Teva Women’s Health has filed suit in the US District Court for New Jersey, claiming that Lupin had filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) which infringes the patents of Seasonale, an oral contraceptive owned by Teva since they bought out Barr last year for $7.6 billion. The purpose of the suit is to prevent sales of the infringing drug.
Seasonale limits the number of menstrual periods women have in a year from 12 (monthly) to 4 (seasonally). the drug has annual sales in the US, exceeding $120 million.
